<SEC-DOCUMENT>0001628280-22-027568.txt : 20221101
<SEC-HEADER>0001628280-22-027568.hdr.sgml : 20221101
<ACCEPTANCE-DATETIME>20221101162133
ACCESSION NUMBER:		0001628280-22-027568
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20221101
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221101
DATE AS OF CHANGE:		20221101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aquestive Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001398733
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				208623253
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38599
		FILM NUMBER:		221350528

	BUSINESS ADDRESS:	
		STREET 1:		30 TECHNOLOGY DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059
		BUSINESS PHONE:		908-941-1900

	MAIL ADDRESS:	
		STREET 1:		30 TECHNOLOGY DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MonoSol Rx, Inc.
		DATE OF NAME CHANGE:	20070507
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aqst-20221101.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:89f5638c-921d-425c-9790-e1d05cacd502,g:904cd2c8-039d-4209-8085-434fe0683c92,d:a1fee74d3d1742299574992da202e46c--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>aqst-20221101</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y180L2ZyYWc6MGY4ZDFmYzMwMTlkNDdlMjk2NjdmYmUyMWMwNzFlNGYvdGFibGU6M2Q1ZmY0YzE3YWI5NDcyNDg0N2EwZGZkNjgwY2ZmMzMvdGFibGVyYW5nZTozZDVmZjRjMTdhYjk0NzI0ODQ3YTBkZmQ2ODBjZmYzM18yLTEtMS0xLTcwMTgz_a87cb589-1f36-4341-83e4-84a85e0f8465">0001398733</ix:nonNumeric><ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y180L2ZyYWc6MGY4ZDFmYzMwMTlkNDdlMjk2NjdmYmUyMWMwNzFlNGYvdGFibGU6M2Q1ZmY0YzE3YWI5NDcyNDg0N2EwZGZkNjgwY2ZmMzMvdGFibGVyYW5nZTozZDVmZjRjMTdhYjk0NzI0ODQ3YTBkZmQ2ODBjZmYzM18zLTEtMS0xLTcwMTgz_f3b4d1e9-a8dc-43f7-a047-9ed240f97f0e">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="aqst-20221101.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia1fee74d3d1742299574992da202e46c_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGV4dHJlZ2lvbjo3OGQ0YjJmZDhmYTU0MThhYjZkNjJmYjk2MWEzMjA5NV8xNDU5_b6b90022-aa09-42ce-8811-9aa7cc553bfb">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) OF THE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGV4dHJlZ2lvbjo3OGQ0YjJmZDhmYTU0MThhYjZkNjJmYjk2MWEzMjA5NV8yMzA_d50d6c23-a06e-415e-9a49-efd22faa8f3a">November&#160;1, 2022</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGV4dHJlZ2lvbjo3OGQ0YjJmZDhmYTU0MThhYjZkNjJmYjk2MWEzMjA5NV8xNDU0_b5b6a502-1d34-474a-9466-f4bd9d944724">Aquestive Therapeutics, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.698%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGFibGU6ZmU5YWFmZDE5YzViNDkzMzk0MmFlYTU0NWI5NDQ4ODgvdGFibGVyYW5nZTpmZTlhYWZkMTljNWI0OTMzOTQyYWVhNTQ1Yjk0NDg4OF8wLTAtMS0xLTcwMTgz_1a26fc5d-fe06-4b7e-b13a-3aee092a6621">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGFibGU6ZmU5YWFmZDE5YzViNDkzMzk0MmFlYTU0NWI5NDQ4ODgvdGFibGVyYW5nZTpmZTlhYWZkMTljNWI0OTMzOTQyYWVhNTQ1Yjk0NDg4OF8wLTEtMS0xLTcwMTgz_7a48b21d-ae1d-40a6-b28b-f86875d75a70">001-38599</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGFibGU6ZmU5YWFmZDE5YzViNDkzMzk0MmFlYTU0NWI5NDQ4ODgvdGFibGVyYW5nZTpmZTlhYWZkMTljNWI0OTMzOTQyYWVhNTQ1Yjk0NDg4OF8wLTItMS0xLTcwMTgz_74996016-3baf-40df-980d-c1f0a0ede665">82-3827296</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGV4dHJlZ2lvbjo3OGQ0YjJmZDhmYTU0MThhYjZkNjJmYjk2MWEzMjA5NV8xNDU1_b007da05-f9bb-4414-b4fe-8ecef8c14bde">30 Technology Drive</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGV4dHJlZ2lvbjo3OGQ0YjJmZDhmYTU0MThhYjZkNjJmYjk2MWEzMjA5NV8xNDYw_255b36b4-349d-4a57-a5ba-ede20273aa9d">Warren</ix:nonNumeric>, <ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGV4dHJlZ2lvbjo3OGQ0YjJmZDhmYTU0MThhYjZkNjJmYjk2MWEzMjA5NV8xNDU2_9773eb56-648b-4db7-a0a9-b9c0b8968534">NJ</ix:nonNumeric> <ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGV4dHJlZ2lvbjo3OGQ0YjJmZDhmYTU0MThhYjZkNjJmYjk2MWEzMjA5NV8xNDUy_eafd8430-31cd-43ce-90ea-1dc58a9427b7">07059</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGV4dHJlZ2lvbjo3OGQ0YjJmZDhmYTU0MThhYjZkNjJmYjk2MWEzMjA5NV8xNDUz_3eb50cb8-3707-422c-8ff7-f753ff88e224">908</ix:nonNumeric>) <ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGV4dHJlZ2lvbjo3OGQ0YjJmZDhmYTU0MThhYjZkNjJmYjk2MWEzMjA5NV8xNDYx_e0f98526-5e2a-4e3f-bb30-597b52c49eb6">941-1900</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:10pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">________________________________________________________________________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:34.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:472.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGFibGU6NWRlM2Q2ZGI3YTM0NDYxNWE3OTUxOWZmZjA3ODUzMTgvdGFibGVyYW5nZTo1ZGUzZDZkYjdhMzQ0NjE1YTc5NTE5ZmZmMDc4NTMxOF8wLTAtMS0xLTcwMTgz_94b087c4-cc4c-40c9-ad56-6853f435d248">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGFibGU6NWRlM2Q2ZGI3YTM0NDYxNWE3OTUxOWZmZjA3ODUzMTgvdGFibGVyYW5nZTo1ZGUzZDZkYjdhMzQ0NjE1YTc5NTE5ZmZmMDc4NTMxOF8yLTAtMS0xLTcwMTgz_a350e3dc-f545-466b-b426-56658d6fd422">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGFibGU6NWRlM2Q2ZGI3YTM0NDYxNWE3OTUxOWZmZjA3ODUzMTgvdGFibGVyYW5nZTo1ZGUzZDZkYjdhMzQ0NjE1YTc5NTE5ZmZmMDc4NTMxOF80LTAtMS0xLTcwMTgz_b1f4da8b-fe7a-488c-945a-1815a8ea3c59">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGFibGU6NWRlM2Q2ZGI3YTM0NDYxNWE3OTUxOWZmZjA3ODUzMTgvdGFibGVyYW5nZTo1ZGUzZDZkYjdhMzQ0NjE1YTc5NTE5ZmZmMDc4NTMxOF82LTAtMS0xLTcwMTgz_f46fd65d-c12f-4d61-81ed-11df5845eb3a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.599%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:2pt solid #000000;border-right:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which<br/>registered</span></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGFibGU6MzYxNDAxOTFmMDhkNDc3ZmE4YWJlMmE2NDc3ODRjNzUvdGFibGVyYW5nZTozNjE0MDE5MWYwOGQ0NzdmYThhYmUyYTY0Nzc4NGM3NV8xLTAtMS0xLTcwMTgz_95d6f681-4100-42af-8be3-0a73bfba563b">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:2pt solid #000000;border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGFibGU6MzYxNDAxOTFmMDhkNDc3ZmE4YWJlMmE2NDc3ODRjNzUvdGFibGVyYW5nZTozNjE0MDE5MWYwOGQ0NzdmYThhYmUyYTY0Nzc4NGM3NV8xLTEtMS0xLTcwMTgz_b4e428c1-9fbf-466b-9f02-b2779ce33225">AQST</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:2pt solid #000000;border-left:2pt solid #000000;border-right:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGFibGU6MzYxNDAxOTFmMDhkNDc3ZmE4YWJlMmE2NDc3ODRjNzUvdGFibGVyYW5nZTozNjE0MDE5MWYwOGQ0NzdmYThhYmUyYTY0Nzc4NGM3NV8xLTItMS0xLTcwMTgz_3d1ded1c-671f-4d74-8332-551ef80dfeea">Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGV4dHJlZ2lvbjo3OGQ0YjJmZDhmYTU0MThhYjZkNjJmYjk2MWEzMjA5NV8xNDU3_88c4bcb7-5e84-47db-8d78-13892fd07cad">&#9746;</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGV4dHJlZ2lvbjo3OGQ0YjJmZDhmYTU0MThhYjZkNjJmYjk2MWEzMjA5NV8xNDU4_f596a375-1e7c-4d4c-ae96-789d7a70ff24">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia1fee74d3d1742299574992da202e46c_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:454.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.02</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations and Financial Condition</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;1, 2022, Aquestive Therapeutics, Inc. (the &#8220;Company&#8221;) issued a press release announcing its reported financial results for the third quarter ended September&#160;30, 2022 and provided an update on recent developments in its business. A copy of the Company&#8217;s press release is attached hereto as Exhibit 99.1 and incorporated by reference.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be &#8220;filed&#8221; for purposes of, or otherwise subject to the liabilities of, Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:454.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements and Exhibits</span></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="aqst-q3x2022xex991.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Press Release, dated November&#160;1, 2022, announcing the Company&#8217;s reported financial results for the third quarter ended September&#160;30, 2022 and providing an update on recent developments in its business.</span></div></td></tr></table></div><div><span><br/></span></div><div id="ia1fee74d3d1742299574992da202e46c_10"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.167%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: November&#160;1, 2022</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aquestive Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ A. Ernest Toth, Jr</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name: A. Ernest Toth, Jr.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title: Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aqst-q3x2022xex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i74b9b34d5a1347e0aca0bb925c6ce946_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><font><br></font></div><div style="text-align:right"><img alt="aqstlogo.jpg" src="aqstlogo.jpg" style="height:33px;margin-bottom:5pt;vertical-align:text-bottom;width:138px"></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">Reported positive data from EPIPHAST II trial comparing AQST-109 (epinephrine sublingual film) to EpiPen&#174; 0.3mg (single dose) and AQST-109 to epi 0.3mg IM injection (repeat dose) </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">Scheduled End-of-Phase 2 (EoP2) meeting with FDA on AQST-109 for fourth quarter 2022 </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">Generated over $25 million in near-term non-dilutive funding through multiple transactions </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">Announces strategic decision to explore US out-licensing opportunities for Libervant (diazepam buccal film)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">Confirms full-year revenue and earnings guidance </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">Hosts investment community conference call on November 2, 2022</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Warren, N.J., November 1, 2022 &#8211; Aquestive Therapeutics, Inc. (NASDAQ&#58; AQST), a pharmaceutical company advancing current standards of care to solve patients&#8217; problems through simplifying complex delivery methods, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent developments in its business.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;We have made significant progress over the last few months in streamlining our business, reducing expenses, and creating a path to an improved financial position, while continuing to rapidly advance our lead asset, AQST-109,&#8221; said Daniel Barber, Chief Executive Officer of Aquestive. &#8220;We continue to believe in the real-world utility of epinephrine sublingual film and look forward to reviewing the data and pivotal program plan with the FDA in our upcoming EoP2 meeting. At the same time, we continue to engage with the FDA on Libervant and are prioritizing the exploration of out-licensing this important product for North America. In the meantime, our manufacturing business continues to generate strong results, thereby allowing us to focus on reducing and potentially refinancing our corporate debt as we progress into 2023.&#8221;    </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Epinephrine</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Aquestive is advancing the development of AQST-109, the first and only orally delivered epinephrine product candidate to have shown clinical results comparable to autoinjectors (such as EpiPen&#174; and Auvi-Q&#174;) for the emergency treatment of allergic reactions, including anaphylaxis.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">According to expert data, nearly 1-in-50 Americans are at chronic risk for acute anaphylactic reactions, however only approximately 3 million prescriptions are filled for injectable epinephrine each year. AQST-109 has the potential to offer these at-risk individuals with an option that overcomes needle phobia and portability challenges seen with existing treatment options. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Aquestive reported positive data from its EPIPHAST II trial comparing AQST-109 to epinephrine 0.3mg intramuscular (IM) injection (repeat dose) and AQST-109 to EpiPen 0.3mg (single dose). The EPIPHAST II trial was designed to compare single doses of AQST-109 to EpiPen 0.3mg and epinephrine 0.3mg IM injection, as well as repeat doses of AQST-109 to repeat doses of epinephrine 0.3mg IM injection. Results from the single dose administration showed AQST-109 achieved a significantly faster median time to maximum concentration (Tmax) Tmax (12 minutes), compared to both EpiPen 0.3mg (22.5 minutes) and epinephrine 0.3mg IM injection (45 minutes). AQST-109 repeat dosing provided significantly higher drug plasma concentrations, with a Tmax of 8 minutes after administration. Results comparing additional pharmacokinetic and pharmacodynamic measures from this study were included in the initial Company press release and supplemental materials dated September 27, 2022. These materials remain available on the Investor page of the Aquestive website.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In September 2022, Aquestive established a Scientific Advisory Board, comprised of eight allergy experts. Each individual on Aquestive&#8217;s advisory board have made significant contributions and breakthroughs in the Allergy and Immunology space.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In October 2022, Aquestive received positive written feedback from the U.S. Food and Drug Administration (FDA) for the Company's initial End-of-Phase 2 (EoP2) meeting request to discuss Chemistry, Manufacturing, and Controls (CMC) for AQST-109. Stability and shelf life are well-documented topics for acute rescue products containing epinephrine. Epinephrine is known to degrade quickly and, as the EpiPen label currently indicates, &#8220;&#91;e&#93;pinephrine solution deteriorates rapidly on exposure to air or light.&#8221; AQST-109 has been designed to minimize exposure to air and light until opened for use. The FDA&#8217;s written response indicates that Aquestive&#8217;s approach to characterizing these and other attributes of AQST-109 &#8220;appear reasonable&#8221; in the context of a potential future filing.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The EoP2 meeting with the FDA to obtain guidance and concurrence on specific questions relating to the clinical components of a potential AQST-109 filing is scheduled during the fourth quarter 2022. At this meeting, Aquestive anticipates receiving feedback on the EPIPHAST study data, as well as the remainder of the proposed clinical development plan for AQST-109.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Libervant&#8482;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Aquestive was granted tentative approval from the FDA for Libervant&#8482;  for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient&#8217;s usual seizure pattern in patients with epilepsy 12 years of age and older. The FDA has concluded that Libervant has met all required quality, safety, and efficacy standards for approval but, due to an existing FDA regulatory grant of orphan drug market exclusivity for Valtoco&#174;, a diazepam nasal spray product, Libervant is not yet eligible for marketing in the United States. As a result of the FDA determination, the Agency cannot give final approval for Libervant until the expiration or inapplicability of the orphan drug market exclusivity, including, for example, by a reversal of the FDA&#8217;s decision and determination that Libervant is &#8220;clinically superior&#8221; to Valtoco within the meaning of FDA&#8217;s regulations, including by establishing a major contribution to patient care relative to the approved product. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Engagement between Aquestive and the FDA is ongoing as the Company has provided its proposed protocol for a head to head clinical study, and is awaiting feedback from the FDA  Concurrently, Aquestive has reached the strategic decision to explore out-licensing opportunities for the North American rights to Libervant (diazepam buccal film).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Out-licensing Activities</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In September 2022, Aquestive entered a license, and supply agreement for Libervant with Pharmanovia, a global lifecycle management healthcare company the &#34;Pharmanovia Agreement&#34;), for the treatment of prolonged or acute, convulsive seizures in all ages, across the European Union, United Kingdom, Switzerland, and Norway, as well as countries in the Middle East and North Africa (MENA).  Pursuant to the Pharmanovia Agreement, Aquestive will serve as the exclusive sole manufacturer and supplier for the product and Pharmanovia will be responsible for all regulatory and commercialization activities relating to the product in those licensed territories. Under the Pharmanovia Agreement, Aquestive received an upfront payment from Pharmanovia of $3.5 million and, if Libervant is approved in the licensed territories, will receive additional milestone payments and double-digit royalties on net sales of Libervant in the licensed territories.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In October 2022, the Company entered into a License Agreement with Otter Pharmaceuticals, LLC, a subsidiary of Assertio Holdings, Inc. (&#8220;Assertio&#8221;), a specialty pharmaceutical company offering differentiated products to patients, to license Sympazan&#174; (clobazam) oral film for the adjunctive treatment of seizures associated with Lennox&#8208;Gastaut syndrome in patients aged two years of age or older (the &#34;Assertio License Agreement&#34;). Under the terms of the Assertio License Agreement, the Company granted an exclusive, worldwide license of its intellectual property for Sympazan to Assertio during the term of the Assertio License Agreement for an upfront payment of $9.0 million.  Under the terms of the Assertio License Agreement, Aquestive will receive a $6.0 million milestone payment within thirty (30) days after Aquestive's receipt of a notice of allowance from the United States Patent and Trademark Office (PTO) of the Company's patent application U.S. Serial No. 16&#47;561,573, and payment by the Company of the related allowance fee. The Company received the notice of allowance from the PTO and paid the related allowance fee on October 27, 2022.  In addition, under the Assertio License Agreement, the Company will receive royalties from Assertio for the sale of the product through the expiration of the Assertio License Agreement. The Company also entered into a long-term supply agreement with </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Assertio, pursuant to which the Company is the exclusive sole worldwide manufacturer and supplier of Sympazan and will receive manufacturing fees from Assertio for the product through the expiration of such supply agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In September 2022, Aquestive received a $7.0 million upfront cash payment from Haisco Pharmaceutical Group for the previously announced licensing and supply agreement for Exservan (riluzole oral film) in China.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Team Expansion</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In August 2022, Aquestive appointed Kenneth Truitt, M.D. as Chief Medical Officer. Dr. Truitt has over 25 years of clinical and regulatory experience across biotechnology and large pharmaceutical companies. Concurrently, Aquestive named Timothy E. Morris to the Company&#8217;s Board of Directors. Mr. Morris brings close to twenty years of pharma industry experience and presently serves as the Chief Financial Officer of Opthea Limited. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Third Quarter 2022 Financials</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total revenues were $11.5 million in the third quarter 2022, compared to $13.3 million in the third quarter 2021.  For the third quarter 2022 compared to the prior year period, the Company saw a 15% increase in Sympazan net revenue and a 15% increase in license and royalty revenue, offset by reductions in manufacture and supply revenue as well as co-development and research fees.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Aquestive&#8217;s net loss for the third quarter 2022 was $12.5 million, or $0.23 loss per share. The net loss for the third quarter 2021 was $14.6 million, or $0.37 loss per share. The change in net loss was primarily driven by a decrease in interest expense, a decrease in non-cash interest expense related to the KYNMOBI&#174; monetization transaction, a decrease in research and development cost and expenses, partially offset by lower revenue.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Adjusted EBITDA loss was $7.7 million in the third quarter 2022, compared to an adjusted EBITDA loss of $5.3 million in the third quarter of 2021. The change in adjusted EBITDA loss year-over-year included a decrease in share-based compensation expense, a decrease in interest expense and a decrease in non-cash interest expense related to the KYNMOBI monetization transaction, partially offset by a lower net loss described above.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Cash and cash equivalents were $18.6 million as of September&#160;30, 2022.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">2022 Outlook</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Aquestive is confirming its full-year 2022 financial outlook. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Company expects&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.000%"><tr><td style="width:1.0%"></td><td style="width:64.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Guidance</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Total revenue (in millions)</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">$46 to $49</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Non-GAAP adjusted EBITDA loss (in millions)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">$37 to $43</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Tomorrow&#8217;s Conference Call and Webcast Reminder</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Company will host a conference call at 8&#58;00 a.m. ET on Wednesday, November 2, 2022. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">A live webcast of the call will be available on Aquestive&#8217;s website at&#58; Third Quarter 2022 Results. The webcast will be archived for 30 days.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About Aquestive Therapeutics</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Aquestive Therapeutics, Inc. (NASDAQ&#58; AQST) is a pharmaceutical company advancing current standards of care to solve patients&#8217; problems by simplifying complex delivery methods. Aquestive is developing pharmaceutical products to deliver complex molecules through alternative administrations to invasive and inconvenient standard of care therapies. Aquestive has five licensed commercialized products which are marketed by our licensees in the U.S. and around the world. The Company is the exclusive manufacturer of these licensed </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm&#174;, and has proven drug development and commercialization capabilities. The Company is advancing an early stage product pipeline for the treatment of severe allergic reactions, including anaphylaxis. The Company has also developed a product pipeline focused on treating diseases of the central nervous system, or CNS. The Company's production facilities are located in Portage, Indiana, and our corporate headquarters, sales and commercialization operations and primary research laboratory facilities are based in Warren, New Jersey. For more information, visit Aquestive.com and follow us on LinkedIn.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i74b9b34d5a1347e0aca0bb925c6ce946_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div id="i74b9b34d5a1347e0aca0bb925c6ce946_7"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Non-GAAP Financial Information</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This press release and our webcast earnings call regarding our quarterly financial results contains financial measures that do not comply with U.S. generally accepted accounting principles (GAAP), such as non-GAAP adjusted EBITDA loss, non-GAAP adjusted gross margins, non-GAAP adjusted costs and expenses and other adjusted expense measures, because such measures exclude, as applicable, share-based compensation expense, interest expense, interest expense related to the sale of future revenue, interest income, depreciation, amortization, and income taxes.&#8239; </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Specifically, the Company adjusts net income (loss) for loss on the extinguishment of debt&#59; certain non-cash expenses, including share-based compensation expenses&#59; depreciation and amortization&#59; and interest expense related to the sale of future revenue, interest income and other income (expense), net and income taxes, with a result of adjusted EBITDA loss.&#8239; Similarly, manufacture and supply expense, research and development expense, and selling, general and administrative expense were adjusted for certain non-cash expenses of share-based compensation expense and depreciation and amortization. Adjusted EBITDA loss and these non-GAAP expense categories are used as a supplement to the corresponding GAAP measures to provide additional insight regarding the Company&#8217;s ongoing operating performance.&#8239; </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">These measures supplement the Company&#8217;s financial results prepared in accordance with GAAP. Aquestive management uses these measures to analyze its financial results, and its future manufacture and supply expenses, gross margins, research and development expense and selling, general and administrative expense and to help make managerial decisions. In management&#8217;s opinion, these non-GAAP measures provide added transparency into the operating performance of Aquestive and added insight into the effectiveness of our operating strategies and actions. The Company may provide one or more revenue measures adjusted for certain discrete items, such as fees collected on certain licensed products, in order to provide investors added insight into our revenue stream and breakdown, along with providing our GAAP revenue. Such measures are intended to supplement, not act as substitutes for, comparable GAAP measures and should not be read as a measure of liquidity for Aquestive. Adjusted EBITDA loss and the other non-GAAP measures are also likely calculated in a way that is not comparable to similarly titled measures reported by other companies. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Non-GAAP Outlook</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In providing the outlook for non-GAAP adjusted EBITDA and non-GAAP gross margin, we exclude certain items which are otherwise included in determining the comparable GAAP financial measures. In order to inform our outlook measures of non-GAAP adjusted EBITDA and non-GAAP gross margin, a description of the 2022 and 2021 adjustments which have been applicable in determining non-GAAP Adjusted EBITDA and non-GAAP gross margin for these periods are reflected in the tables below. In providing outlook for non-GAAP gross margin, the Company adjusts for non-cash share-based compensation expense and depreciation and amortization. The Company is providing such outlook only on a non-GAAP basis because the Company is unable to predict with reasonable certainty the totality or ultimate outcome or occurrence of these adjustments for the forward-looking period such as share-based compensation expense, income tax, amortization, and certain other adjusted items, which can be dependent on future events that may not be reliably predicted. Based on past reported results, where one or more of these items have been applicable, such excluded items could be material, individually or in the aggregate, to reported results.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i74b9b34d5a1347e0aca0bb925c6ce946_10"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Forward-Looking Statement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Certain statements in this press release are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, clinical advancement and related timing of AQST-109 through the regulatory and development pipeline&#59; the potential for AQST-109 as the first orally administered epinephrine product candidate for the treatment of anaphylaxis&#59; statements regarding the approval of Libervant by the FDA for U.S. market access and potential out-licensing of Libervant in North America&#59; potential refinancing of the Company's current corporate debt&#59; profitability of the Company's manufacturing operations and the 2022 financial outlook of the Company&#59; and business strategies, market opportunities, and other statements that are not historical facts. These forward-looking statements are subject to the uncertain impact of the COVID-19 global pandemic on our business including with respect to our clinical trials including site initiation, patient enrollment and timing and adequacy of clinical trials&#59; on regulatory submissions and regulatory reviews and approvals of our product candidates&#59; pharmaceutical ingredient and other raw materials supply chain, manufacture, and distribution&#59; sale of and demand for our products&#59; our liquidity and availability of capital resources&#59; customer demand for our products and services&#59; customers&#8217; ability to pay for goods and services&#59; and ongoing availability of an appropriate labor force and skilled professionals. Given these uncertainties, the Company is unable to provide assurance that operations can be maintained as planned prior to the COVID-19 pandemic. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">These forward-looking statements are also based on our current expectations and beliefs and are subject to a due number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company's development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials and plans for AQST-109, AQST-108 and our other drug candidates&#59; risk of delays in regulatory advancement through the FDA of Libervant, AQST-109, AQST-108, and our other drug candidates or failure to receive approval, including the risk that the FDA may require additional clinical studies for FDA approval of Libervant for U.S. market access&#59; risk of our ability to demonstrate to the FDA the &#8220;clinical superiority&#8221; of Libervant within the meaning of the FDA regulations relative to FDA-approved Valtoco&#174; (diazepam)  spray product of another company, including by establishing a major contribution to patient care within the meaning of FDA regulations relative to the approved product, as well as risks related to other potential pathways or positions which are or may in the future be advanced to the FDA to overcome the seven year orphan drug exclusivity granted by the FDA for the approved nasal spray product in the U.S., and there can be no assurance that the Company will be successful&#59; risk that a competitor obtains FDA orphan drug exclusivity for a product with the same active moiety as any of our other drug product candidates for which we are seeking FDA approval and that such earlier approved competitor orphan drug blocks such other product candidates in the U.S. for seven years for the same indication&#59; risk that a competitor will obtain other market exclusivity with respect to our product candidates&#59; risk in obtaining market access for our product candidates for other reasons&#59; risk inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks and regulatory limitations)&#59; risk of our ability to out-license our proprietary products&#59; risk of development of our sales and marketing capabilities&#59; risk of legal costs associated with and the outcome of our patent litigation challenging third party at risk generic sale of our proprietary products and other litigation matters in which we are involved&#59; risk of sufficient capital and cash resources, including access to available debt and equity financing, including under the Company's At-The-Market facility and other current equity facility, and revenues from operations, to satisfy all of our short-term and longer term cash requirements and other cash needs, at the times and in the amounts needed, or at all&#59; risks and uncertainties concerning the royalty and other revenue stream of the KYNMOBI&#174; monetization transaction, achievement of royalty targets worldwide or in any jurisdiction and certain other commercial targets required for contingent payments under the monetization transaction&#59; risk of failure to satisfy all financial and other debt covenants and of any default&#59; short-term and long-term liquidity and cash requirements, cash funding and cash burn&#59; risk that we are unable to refinance our current corporate debt on terms and conditions satisfactory to the Company, or not at all&#59; risk related to government claims against Indivior for which we license, manufacture and sell Suboxone&#174; and which accounts for the substantial part of our current operating revenues&#59; risk of eroding market share for Suboxone and risk of a sunsetting product&#59; risks related to the outsourcing of certain marketing and other operational and staff functions to third parties&#59; risk of the rate and degree of market acceptance of our product and product candidates&#59; the success of any competing products, including generics&#59; risk of the size and growth of our product markets&#59; risks of compliance with all FDA and other governmental and customer requirements for our manufacturing facilities&#59; risks associated with intellectual property rights and infringement claims relating to the Company's products&#59; risk of unexpected patent developments&#59; the impact of existing and future legislation and regulatory provisions on product exclusivity&#59; legislation or regulatory </font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">actions affecting pharmaceutical product pricing, reimbursement or access&#59; claims and risks that may arise regarding the safety or efficacy of the Company's products and product candidates&#59; including anticipated sales of Sympazan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#59; risk of loss of significant customers&#59; risks related to legal proceedings, including patent infringement, securities, business torts, investigative and antitrust litigation matters&#59; changes in government laws and regulations&#59; risk of product recalls and withdrawals&#59; uncertainties related to general economic, political, business, industry, regulatory and market conditions and other unusual items&#59; and other uncertainties affecting the Company described in the &#8220;Risk Factors&#8221; section and in other sections included in our Annual Report on Form 10-K, in our Quarterly Reports on Form 10-Q, and in our Current Reports on Form 8-K filed with the Securities Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">PharmFilm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, Sympazan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.   All other registered trademarks referenced herein are the property of their respective owners.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Investor inquiries&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ICR Westwicke</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Stephanie Carrington</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">stephanie.carrington&#64;westwicke.com</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">646-277-1282</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i74b9b34d5a1347e0aca0bb925c6ce946_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AQUESTIVE THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:70.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br>2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2021</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,649&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,024&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade and other receivables, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,737&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,120&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,725&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,038&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,077&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,087&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,259&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,284&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,055&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,094&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,487&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,893&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,903&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,845&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,993&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; deficit</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,072&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,314&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,733&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,736&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future revenue, current</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,910&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans payable, current</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,225&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,025&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,560&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,964&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans payable, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,675&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,551&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future revenue, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,308&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,059&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,946&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,622&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,122&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,159&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,664&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,127&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingencies</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; deficit&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $0.001 par value. Authorized 250,000,000 shares&#59; 53,852,126 and 41,228,736 shares issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021, respectively</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,982&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,621&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(298,855)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256,796)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; deficit</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,819)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,134)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; deficit</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,845&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,993&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i74b9b34d5a1347e0aca0bb925c6ce946_16"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AQUESTIVE THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,463&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,287&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,998&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,754&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacture and supply</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,625&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,400&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,081&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,623&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,232&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,726&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,203&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,647&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,459&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,129&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,067&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,494&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,316&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,255&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,351&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,764&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,853)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,968)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,353)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,010)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income&#47; (expenses)&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,649)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,787)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,902)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,305)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense related to the sale of future revenue, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,039)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,767)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,837)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,567)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income (expense), net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,536)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,555)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,058)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,594)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,536)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,555)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,058)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,594)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,536)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,555)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,058)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,594)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.90)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.12)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding - basic and diluted</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,424,922&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,224,863&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,828,218&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,297,892&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:5pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i74b9b34d5a1347e0aca0bb925c6ce946_19"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AQUESTIVE THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Non-GAAP Adjustments - Net Loss to Adjusted EBITDA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In Thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited) </font></div><div><font><br></font></div><div style="margin-top:5pt"><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,536)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,555)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,058)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,594)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based Compensation Expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,669&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,128&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,787&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,902&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,305&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense related to the sale of future revenue, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,039&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,767&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,837&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,567&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other (income) expense, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and Amortization</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,990&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,233&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-GAAP adjustments</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,814&#160;</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,223&#160;</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,364&#160;</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,945&#160;</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,722)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,332)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,694)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,649)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i74b9b34d5a1347e0aca0bb925c6ce946_22"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AQUESTIVE THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Non-GAAP Adjustments - GAAP Expenses to Adjusted Expenses</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In Thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited) </font></div><div><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,316&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,255&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,351&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,764&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(535)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,900)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,669)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,128)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(596)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(736)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,990)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,233)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted costs and expenses</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,185&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,619&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,692&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,403&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div id="i74b9b34d5a1347e0aca0bb925c6ce946_25"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AQUESTIVE THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Non-GAAP Adjustments - GAAP Manufacture &#38; Supply Expense to Adjusted Manufacture and Supply Expense</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In Thousands, except percentages)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited) </font></div><div><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacture and Supply Expense</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,625&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,400&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,081&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,623&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross Margin on total revenue</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">60&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">67&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">62&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">71&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP adjustments&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(459)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(579)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,573)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,744)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted manufacture and supply expense</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,100&#160;</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,733&#160;</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,349&#160;</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,638&#160;</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Non-GAAP Gross Margin on total revenue</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">64&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">72&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">67&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">76&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i74b9b34d5a1347e0aca0bb925c6ce946_28"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AQUESTIVE THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Non-GAAP Adjustments - GAAP Research and Development Expense to Adjusted Research and Development Expense</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In Thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Development Expense</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,232&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,726&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,203&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,647&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(670)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted research and development expense</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,114&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,445&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,661&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,817&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div id="i74b9b34d5a1347e0aca0bb925c6ce946_31"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AQUESTIVE THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Non-GAAP Adjustments - GAAP Selling, General and Administrative Expenses to Adjusted Selling, General and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Administrative Expenses</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In Thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited) </font></div><div><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, General and Administrative Expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,459&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,129&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,067&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,494&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,582)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,104)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,217)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted selling, general and administrative expenses</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,971&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,441&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,682&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,948&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>aqst-20221101.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:89f5638c-921d-425c-9790-e1d05cacd502,g:904cd2c8-039d-4209-8085-434fe0683c92-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:aqst="http://aquestive.com/20221101" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://aquestive.com/20221101">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="aqst-20221101_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="aqst-20221101_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://aquestive.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>aqst-20221101_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:89f5638c-921d-425c-9790-e1d05cacd502,g:904cd2c8-039d-4209-8085-434fe0683c92-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_86540512-7e79-44cf-a037-a0e60ebeeaf0_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_662b6ebe-27ee-4173-8d85-8fe1a2f1f5a9_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_03e665a7-39fa-4a46-a673-536cefaad388_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_b393aa3b-7874-406c-ae88-c15a6e6cc080_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_0b2e7738-dfef-4e73-9239-78720ce63fa8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b004b9cb-7226-4815-8804-558e6587e39e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c8066627-0ded-42f2-a687-8e9b8762fdde_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_5523ce40-d9d7-422a-962d-9aeee8939622_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_176dad2a-5ade-4411-b37f-d8b1b41b13ba_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e5876ac8-79f4-40f3-908e-462b1d58dc44_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_cf268f4c-47ac-4ce2-9d0d-59619adb72e7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5e848a79-9c09-4206-a9df-6dc6dc0bea20_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_9d238956-ceed-4da1-91de-b55aef59bbfa_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f330d822-9628-4884-8412-735e0340cbac_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b077a268-c5f4-46ae-982d-46d887f3ae1a_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_20e3c84b-e054-460f-b940-a2428abea5f0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6577e37a-7232-49bc-88f1-b8637bb04fbb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a048ccc6-9e96-47cc-a667-3ef04d1f69a0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6d306c51-8ba0-4548-acf3-891c8e417413_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5113c2a1-ebf2-4d9b-97ad-d7b453010e9a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_77e50e77-116e-4c66-9c7f-fe259eaa892f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_bd9dfc5a-b03f-4e5f-a6f8-680fdc65730c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_807a2204-f399-4e32-9a04-f321ff6f22a5_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>aqst-20221101_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:89f5638c-921d-425c-9790-e1d05cacd502,g:904cd2c8-039d-4209-8085-434fe0683c92-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://aquestive.com/role/Cover" xlink:type="simple" xlink:href="aqst-20221101.xsd#Cover"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3c3bcbf3-6a05-4a50-ab97-25670eab448c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_DocumentType_3c3bcbf3-6a05-4a50-ab97-25670eab448c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e3e59a83-ebe6-4ce4-ab60-1612abdf5d44" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_DocumentPeriodEndDate_e3e59a83-ebe6-4ce4-ab60-1612abdf5d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_87d3c3c7-c1cd-42ef-ab9e-6e1a4678e2be" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_EntityRegistrantName_87d3c3c7-c1cd-42ef-ab9e-6e1a4678e2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_102d50e7-495c-46c4-83dd-1b5ab3ede0da" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_102d50e7-495c-46c4-83dd-1b5ab3ede0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f9d003fb-d72a-475a-9f9c-18eb109166ec" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_EntityFileNumber_f9d003fb-d72a-475a-9f9c-18eb109166ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_171b3cbd-aa9d-4612-9c31-4c6db669b638" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_EntityTaxIdentificationNumber_171b3cbd-aa9d-4612-9c31-4c6db669b638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f2734826-95ea-4196-b83a-ec4094749705" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_EntityAddressAddressLine1_f2734826-95ea-4196-b83a-ec4094749705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_59bf24fc-8e36-4539-bba7-7d80a34f9596" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_EntityAddressCityOrTown_59bf24fc-8e36-4539-bba7-7d80a34f9596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_075dc6fd-e497-43e2-8543-23db9df3be73" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_EntityAddressStateOrProvince_075dc6fd-e497-43e2-8543-23db9df3be73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7191f559-c6af-4e9f-b465-d9dd5d9f131b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_EntityAddressPostalZipCode_7191f559-c6af-4e9f-b465-d9dd5d9f131b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7f9cc6f2-3d5a-4305-bdf9-533d84ace6b8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_CityAreaCode_7f9cc6f2-3d5a-4305-bdf9-533d84ace6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1b7755a3-9fd1-4d1b-9067-0e0340ec5566" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_LocalPhoneNumber_1b7755a3-9fd1-4d1b-9067-0e0340ec5566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_e07c3466-9cf3-4ab6-a444-a5c16d0e4164" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_WrittenCommunications_e07c3466-9cf3-4ab6-a444-a5c16d0e4164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_506a4dad-af61-48a1-a466-29f060462fb6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_SolicitingMaterial_506a4dad-af61-48a1-a466-29f060462fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_a9fa9753-9add-4f6b-9bd1-1bdf1dae4f0b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_PreCommencementTenderOffer_a9fa9753-9add-4f6b-9bd1-1bdf1dae4f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_08e4b730-c5ab-474a-84d9-4a404bf125e2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_08e4b730-c5ab-474a-84d9-4a404bf125e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_787ad5e8-0972-4bf4-8c1e-d8684cb98c67" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_Security12bTitle_787ad5e8-0972-4bf4-8c1e-d8684cb98c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e8f7e532-2b4b-4bd1-8ab2-6c407ee4d141" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_TradingSymbol_e8f7e532-2b4b-4bd1-8ab2-6c407ee4d141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f9cbc88c-69be-4f2b-83d9-b87cb9eb4bf8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_SecurityExchangeName_f9cbc88c-69be-4f2b-83d9-b87cb9eb4bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_83f4a0b1-ae09-41ea-ba14-78d1c3da3cb2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_EntityEmergingGrowthCompany_83f4a0b1-ae09-41ea-ba14-78d1c3da3cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_519a5e41-8fc1-46b0-9ae3-5401c62eca96" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_EntityExTransitionPeriod_519a5e41-8fc1-46b0-9ae3-5401c62eca96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ccfd2955-fe80-4ef9-8037-31644764c389" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_EntityCentralIndexKey_ccfd2955-fe80-4ef9-8037-31644764c389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_88907329-2084-425e-8636-ea7e4f6cecda" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2561f0-1cdd-47bd-93d5-6b6b32c8e77d" xlink:to="loc_dei_AmendmentFlag_88907329-2084-425e-8636-ea7e4f6cecda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>aqstlogo.jpg
<TEXT>
begin 644 aqstlogo.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-A;6%N=&AA
M+DUA<VME    !9 #  (    4   0J) $  (    4   0O)*1  (    #-S<
M )*2  (    #-S<  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C Z,3(Z,#,@,34Z-3DZ,#0 ,C R,#HQ
M,CHP,R Q-3HU.3HP-    %, 80!M &$ ;@!T &@ 80 N $T 80!S &L 90
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" !F :,# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M1SA54NQ/H.37R-XP^(WB&[\6Z@]IJ4BPI.Z1K&>-@)Q^E SZ\+_W2/Q-+O\
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MZ/&9>N=QQ^6:B\<Z18Z5\-=4AT^UC@00-]Q<$_*>] 'REX2&/&FBX_Y_X?\
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M+:QA<21N2"1CTQ7O:9VC-?-8NT:W/!GN8=2<.69XK=?#348?$"00JSVK-E9
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M% !M%&*** %Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@
FQ1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140716582456176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  01,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Aquestive Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3827296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">30 Technology Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Warren<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">941-1900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AQST<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001398733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>aqst-20221101_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="aqst-20221101.xsd" xlink:type="simple"/>
    <context id="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y180L2ZyYWc6MGY4ZDFmYzMwMTlkNDdlMjk2NjdmYmUyMWMwNzFlNGYvdGFibGU6M2Q1ZmY0YzE3YWI5NDcyNDg0N2EwZGZkNjgwY2ZmMzMvdGFibGVyYW5nZTozZDVmZjRjMTdhYjk0NzI0ODQ3YTBkZmQ2ODBjZmYzM18yLTEtMS0xLTcwMTgz_a87cb589-1f36-4341-83e4-84a85e0f8465">0001398733</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y180L2ZyYWc6MGY4ZDFmYzMwMTlkNDdlMjk2NjdmYmUyMWMwNzFlNGYvdGFibGU6M2Q1ZmY0YzE3YWI5NDcyNDg0N2EwZGZkNjgwY2ZmMzMvdGFibGVyYW5nZTozZDVmZjRjMTdhYjk0NzI0ODQ3YTBkZmQ2ODBjZmYzM18zLTEtMS0xLTcwMTgz_f3b4d1e9-a8dc-43f7-a047-9ed240f97f0e">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGV4dHJlZ2lvbjo3OGQ0YjJmZDhmYTU0MThhYjZkNjJmYjk2MWEzMjA5NV8xNDU5_b6b90022-aa09-42ce-8811-9aa7cc553bfb">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGV4dHJlZ2lvbjo3OGQ0YjJmZDhmYTU0MThhYjZkNjJmYjk2MWEzMjA5NV8yMzA_d50d6c23-a06e-415e-9a49-efd22faa8f3a">2022-11-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGV4dHJlZ2lvbjo3OGQ0YjJmZDhmYTU0MThhYjZkNjJmYjk2MWEzMjA5NV8xNDU0_b5b6a502-1d34-474a-9466-f4bd9d944724">Aquestive Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGFibGU6ZmU5YWFmZDE5YzViNDkzMzk0MmFlYTU0NWI5NDQ4ODgvdGFibGVyYW5nZTpmZTlhYWZkMTljNWI0OTMzOTQyYWVhNTQ1Yjk0NDg4OF8wLTAtMS0xLTcwMTgz_1a26fc5d-fe06-4b7e-b13a-3aee092a6621">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGFibGU6ZmU5YWFmZDE5YzViNDkzMzk0MmFlYTU0NWI5NDQ4ODgvdGFibGVyYW5nZTpmZTlhYWZkMTljNWI0OTMzOTQyYWVhNTQ1Yjk0NDg4OF8wLTEtMS0xLTcwMTgz_7a48b21d-ae1d-40a6-b28b-f86875d75a70">001-38599</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGFibGU6ZmU5YWFmZDE5YzViNDkzMzk0MmFlYTU0NWI5NDQ4ODgvdGFibGVyYW5nZTpmZTlhYWZkMTljNWI0OTMzOTQyYWVhNTQ1Yjk0NDg4OF8wLTItMS0xLTcwMTgz_74996016-3baf-40df-980d-c1f0a0ede665">82-3827296</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGV4dHJlZ2lvbjo3OGQ0YjJmZDhmYTU0MThhYjZkNjJmYjk2MWEzMjA5NV8xNDU1_b007da05-f9bb-4414-b4fe-8ecef8c14bde">30 Technology Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGV4dHJlZ2lvbjo3OGQ0YjJmZDhmYTU0MThhYjZkNjJmYjk2MWEzMjA5NV8xNDYw_255b36b4-349d-4a57-a5ba-ede20273aa9d">Warren</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGV4dHJlZ2lvbjo3OGQ0YjJmZDhmYTU0MThhYjZkNjJmYjk2MWEzMjA5NV8xNDU2_9773eb56-648b-4db7-a0a9-b9c0b8968534">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGV4dHJlZ2lvbjo3OGQ0YjJmZDhmYTU0MThhYjZkNjJmYjk2MWEzMjA5NV8xNDUy_eafd8430-31cd-43ce-90ea-1dc58a9427b7">07059</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGV4dHJlZ2lvbjo3OGQ0YjJmZDhmYTU0MThhYjZkNjJmYjk2MWEzMjA5NV8xNDUz_3eb50cb8-3707-422c-8ff7-f753ff88e224">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGV4dHJlZ2lvbjo3OGQ0YjJmZDhmYTU0MThhYjZkNjJmYjk2MWEzMjA5NV8xNDYx_e0f98526-5e2a-4e3f-bb30-597b52c49eb6">941-1900</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGFibGU6NWRlM2Q2ZGI3YTM0NDYxNWE3OTUxOWZmZjA3ODUzMTgvdGFibGVyYW5nZTo1ZGUzZDZkYjdhMzQ0NjE1YTc5NTE5ZmZmMDc4NTMxOF8wLTAtMS0xLTcwMTgz_94b087c4-cc4c-40c9-ad56-6853f435d248">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGFibGU6NWRlM2Q2ZGI3YTM0NDYxNWE3OTUxOWZmZjA3ODUzMTgvdGFibGVyYW5nZTo1ZGUzZDZkYjdhMzQ0NjE1YTc5NTE5ZmZmMDc4NTMxOF8yLTAtMS0xLTcwMTgz_a350e3dc-f545-466b-b426-56658d6fd422">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGFibGU6NWRlM2Q2ZGI3YTM0NDYxNWE3OTUxOWZmZjA3ODUzMTgvdGFibGVyYW5nZTo1ZGUzZDZkYjdhMzQ0NjE1YTc5NTE5ZmZmMDc4NTMxOF80LTAtMS0xLTcwMTgz_b1f4da8b-fe7a-488c-945a-1815a8ea3c59">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGFibGU6NWRlM2Q2ZGI3YTM0NDYxNWE3OTUxOWZmZjA3ODUzMTgvdGFibGVyYW5nZTo1ZGUzZDZkYjdhMzQ0NjE1YTc5NTE5ZmZmMDc4NTMxOF82LTAtMS0xLTcwMTgz_f46fd65d-c12f-4d61-81ed-11df5845eb3a">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGFibGU6MzYxNDAxOTFmMDhkNDc3ZmE4YWJlMmE2NDc3ODRjNzUvdGFibGVyYW5nZTozNjE0MDE5MWYwOGQ0NzdmYThhYmUyYTY0Nzc4NGM3NV8xLTAtMS0xLTcwMTgz_95d6f681-4100-42af-8be3-0a73bfba563b">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGFibGU6MzYxNDAxOTFmMDhkNDc3ZmE4YWJlMmE2NDc3ODRjNzUvdGFibGVyYW5nZTozNjE0MDE5MWYwOGQ0NzdmYThhYmUyYTY0Nzc4NGM3NV8xLTEtMS0xLTcwMTgz_b4e428c1-9fbf-466b-9f02-b2779ce33225">AQST</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGFibGU6MzYxNDAxOTFmMDhkNDc3ZmE4YWJlMmE2NDc3ODRjNzUvdGFibGVyYW5nZTozNjE0MDE5MWYwOGQ0NzdmYThhYmUyYTY0Nzc4NGM3NV8xLTItMS0xLTcwMTgz_3d1ded1c-671f-4d74-8332-551ef80dfeea">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGV4dHJlZ2lvbjo3OGQ0YjJmZDhmYTU0MThhYjZkNjJmYjk2MWEzMjA5NV8xNDU3_88c4bcb7-5e84-47db-8d78-13892fd07cad">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZmVlNzRkM2QxNzQyMjk5NTc0OTkyZGEyMDJlNDZjL3NlYzphMWZlZTc0ZDNkMTc0MjI5OTU3NDk5MmRhMjAyZTQ2Y18xL2ZyYWc6NzhkNGIyZmQ4ZmE1NDE4YWI2ZDYyZmI5NjFhMzIwOTUvdGV4dHJlZ2lvbjo3OGQ0YjJmZDhmYTU0MThhYjZkNjJmYjk2MWEzMjA5NV8xNDU4_f596a375-1e7c-4d4c-ae96-789d7a70ff24">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *^"854'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "O@F%5<\U>(^T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>R'9@!Y/ZLK'3"H45-G8SMMJ:Q8FQ-9*^_9RL31G; ^QHZ?>G
M3Z#61F6'A+LT1$SD,=]-H>NSLG'#3D11 61[PF!R71)]:1Z&% R59SI"-/;#
M'!$DY_<0D(PS9& &5G$E,MTZJVQ"0T.ZX)U=\?$S=0O,6< . _:40=0"F)XG
MQO/4M7 #S##"%/)W =U*7*I_8I<.L$MRRGY-C>-8C\V2*SL(>-L^ORSK5K[/
M9'J+Y5?VBLX1-^PZ^;5Y>-P_,2VYE)40%1=[R944JA'OL^L/OYMP&)P_^']L
M?!74+?RZ"_T%4$L#!!0    ( *^"85697)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
MKX)A52L\EU9C!   &A$  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6R=
MF&MSXC84AO^*QMWIM#-)? $"I, ,(<DVW=TL&V@STTX_"%M@36S)*\E<_OT>
M&6+367/,]@NVC,_+(YVC5Q*#C52O.F;,D&V:"#UT8F.R&]?58<Q2JJ]DQ@1\
MLY0JI0:::N7J3#$:%4%IX@:>=^VFE MG-"B>3=5H('.3<,&FBN@\3:G:W;)$
M;H:.[[P]>.:KV-@'[FB0T16;,?-G-E70<DN5B*=,:"X%46PY=,;^S6W0L0'%
M&W]QMM%']\1V92'EJVT\1D/'LT0L8:&Q$A0N:S9A26*5@./K0=0I?],&'M^_
MJ3\4G8?.+*AF$YF\\,C$0Z?GD(@M:9Z89[GYG1TZ5 "&,M'%)]GLWVVW'1+F
MVLCT$ P$*1?[*]T>!N(XP#\1$!P"@H)[_T,%Y1TU=#10<D.4?1O4[$W1U2(:
MX+BP69D9!=]RB#.CB5PS-7 -2-D';G@(N]V'!2?"GN3ZBGC^!0F\(/AON L$
M)4908@2%7@O#(/^,%]HH2-2_=41[A7:]@JW>&YW1D T=*$_-U)HYHY]_\J^]
MWQ"^5LG7PM1'=S+,H18-F>\R5@>'A_<N/R 0[1*B?1[$E"DN(W(O(@))K^7!
ME8KT%?EK2F"G9.N@BO?"<+,CSVS%;0H!\HFFM62XSOAKSK2=J&0>,T4SEAL>
MZ@OR*,(K!/.ZQ+P^!Q/4I,JDHM89+LC,P"@2J<A$YL*H'5RC6G9<_.X>(>R6
MA-US"!]XPLA3GB[J9R>NX7G^9:O7Z?<1GE[)TSN'9TZWY#&"XN-+'A;#AM#A
MBKT X()NT+]&\/HE7O\<O'$4P:2'.CG<D(_P'ODL:K.(*[8\,F=A+&0B5SMR
MIZ 6$4[?JXS6^R'2B6U!S<WE1M0:,"[W0I5B B,[6@+\'R(KI\-4R3478>T@
M-F@^_8&A5<N"C[KZ=VA3J0U-R-\\.SE'&Q2]KM?!YH5?+0D^;NI% L>P%3J-
M@@OTO1X&4BT+/N[F'V4(8S*-I< LHT&DW_8O_;[G84358N#C+OZBN#%,P,"D
M:2X.AJ%KJ7"A)4TT.OTJX_=Q<Y[)A(?<<+$BGZ"\%:=)+0^NTLA3V;R/>_14
ML<L0AH?!_-KO+)B(8 _T>;D\D3]<KY&L,GP?]^?OR!ZUSH&L$1"7;02L+-_'
M'7K.#2R.<DG\X)?%KV3&PASJ;5?+A"O9^H25;&9D^'I!,JK(FB8Y(^^\*UA#
M20;=U3%5&'90+0 ![MAS12-;?K-=NI"UQ=<@,/XRFV,DE>$'N#F_C1BYWX8Q
M%2MV<K/6(/0TGMV-OV!,1P> LYS^/F5J94?I/2B8V#I(1D5M;AL$C<K1O%4^
M'^ V_4:V)9!!.(X6FY_]%KP6"U=KF@9!9?L![M@'K@E,407^_PBS<TL^L/JQ
MPJ4\J/96O]=MM3"RROZ#ADT\V$946,=#0E>U//_3]MVCDZ[]U^ 3M=6B2<*6
M(.1==4%7[0_B^X:167'X74@#1^GB-F84?,R^ -\OI31O#7N>+O\.&7T#4$L#
M!!0    ( *^"856?H!OPL0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;
M,!#^*T(_8&YB:N*1&+9 8;"-0O-A7Y58=@1Z\62Y<_KKI[-L)VEU9=V'L<VA
MR=T]NKM'=R>9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;
M)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/
M3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O
M_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_
M/LG>V)+;.<V"3J9B+7D%=*RHC_#K3), Z)Q17B@%JXUF X?)8Q1\V .7\@%:
M^*VZBMU7)/3B4PEM(+#52?2$1C&$"0K$OXP68E^$O?VML*01C\9][/QN]*!_
M[XSC]Y97HA_TOIKS8]$7>'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!
M6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<
M'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72
M[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'
M')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^
M6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]
M?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1
M/,<0F,7XC&894IT,/O'^8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\E
MTWLJ.?]74_P$4$L#!!0    ( *^"8567BKL<P    !,"   +    7W)E;',O
M+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +
M&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P
M6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,
M-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4
M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ KX)A5:K$(A8S 0  (@(   \
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M4$L! A0#%     @ KX)A57/-7B/M    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ KX)A59E<G",0!@  G"<
M !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " "O@F%5*SR75F,$   :$0  &               @($,"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ KX)A59^@&_"Q @  X@P
M  T              ( !I0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "O
M@F%5EXJ[',     3 @  "P              @ &!#P  7W)E;',O+G)E;'-0
M2P$"% ,4    " "O@F%5JL0B%C,!   B @  #P              @ %J$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ KX)A520>FZ*M    ^ $  !H
M             ( !RA$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ KX)A5660>9(9 0  SP,  !,              ( !KQ(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ^1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="aqst-20221101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="aqst-20221101.htm">aqst-20221101.htm</File>
    <File>aqst-20221101.xsd</File>
    <File>aqst-20221101_lab.xml</File>
    <File>aqst-20221101_pre.xml</File>
    <File>aqst-q3x2022xex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "aqst-20221101.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "aqst-20221101.htm"
     ]
    },
    "labelLink": {
     "local": [
      "aqst-20221101_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aqst-20221101_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "aqst-20221101.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "aqst",
   "nsuri": "http://aquestive.com/20221101",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "aqst-20221101.htm",
      "contextRef": "ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "role": "http://aquestive.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "aqst-20221101.htm",
      "contextRef": "ic8246847a4a34cbb91b618d9347c5f6d_D20221101-20221101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-22-027568-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-027568-xbrl.zip
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MHMBF\:RZ-[JKLJR6O!Y4YV*7KJLGR^M?5RTE$>W%;A@%-($-%R!)6%*PK,P
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MK9(#F,RC0K:)TW*89!B5IP.X@&G8I8'GC\O_;GD!\(LZ'Z)F&-#>O[=C4&E
M]XD\-ZL8>Q->E@GL1_HXS. WH)]T\Z:8I(C5/*D?M:H5=-S::U6/YW'G#<[V
MN+I_TCQJ'56/T5Z]@JK_[/]WKWY81?N-6NWH^/BH47]%$)250#BE<1=P)0E[
MVZBR#Z:,1JR%2=]-T.E_+TNSP&>*4D9Z+TZTZD\2[=LD27,E##EH-&OH&17
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MN]4STW2([=@&UK@IKLUA-C:986)9-2W%99+A4)9[4/6[/:AKRCC<>UC!-C"
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MM 2EN12C( Y)@$ P67 Q'P7W=[<X#:[&O=[E!XP?/T\GZ$:RM@9AT+4":J!
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M_K-VJWO3W+)GW?\:YX[YM2PNT^SR]R*_*Z_T7#<L>YA+?8*,&2<@ILHTS54
M*"1Z]< H\45$! _#@4WSKGF.;;G8-(776KV56&^M=G#KO--:Z^[Y6,,F:J /
M],JEA[[-B3%M],ZX4W?2MR77T4S?.GSX(G!1,',M]]>'ZR1?S+E"F*B0@S!F
M^@>7"% !!8@H]BD328QD;(M](_*Q@;X6YZW4V8/=M&LWRLXF'+I#9I?_(%@[
M<W7"LQEI,B [$Z@CV#U@.'2;FR0>KPS^C95R'DD2$A930#FDYAX&#!@5"F#!
M]3^82(:L-ZH[9S@V"!_O%5FI]+1,S^BTQ[';R-U8CK;GP'@.=F80J%NS=P*V
M.^)DX&Y-J [P]H$.FT[Y(N5IJ=>$/W2@(F6+.14H(#3"@$O3UQ;,!]37Y]U)
M%#&I(IHDROILNQW^V!!^4NAM) [8=&J[9['M-,J3 W,[Q(YAFTZ]6;MM.[7#
M3;?QU)M*8^NI?Y1[O;W0+YVK((""(&2:V@2$A(2 A.;^C""2, @A3Q@?6F9-
MX&-#\[&&&''#2VKEE7TE'>K 5 5T:_).5;.>Z:AB606:O$;6Y7>5QL;?AZ-V
M9J[M+"0[RX6Y!"..F3ZC!#PR723,)* $Z:J(!2&Q"ICTK6MA/?"QH79674:L
MQ7E&G3UK#;-VL^9JP8%9L\Q^$&Q=J3K!U@@T&6Q=\NNP=?[=M8/[(>-Y<9,7
MU4Y2=4'U67Z;E<5#];%"4 :<A F0,#(,0@42&D+ 4(B(CL@B^_L/+>8[-C37
M7<J&YMJ5_FOE [FU\=VVS;LW-Z=I]XXRTJ'W:V7/B![P]O@3]X*MDFWWA.U>
M-O(NJ_5_YVDF_3F.XE@&,0,Q"A (:<(!(<H'"<%!G"0P5$GB=(M5?98C74H>
M;Q=:/_",6.]3YGI[5<-8VU5CI%W3K!7#G7*_KZK+B?$W536B_IP[JKH2Z[V=
MJG.P*_A?Y&6Z+ N6E1_U>SUG,"2<<PRHI!B$,>> 81R#0"H8"E]AR@8>2#0G
M.%+<GT1Z1N50R)^9:,NWNS73H&WKB@/0W:F/8/E9P(DQ[DZG37#/N.'PFF^.
M6GR^RK/-!<-8!!#SR <D81"$44@ XRH A/J<R-"/0S^P!?=Y\&.#MM+G50('
M7VG=,FXWK&/L.#"H YP8!&E?RDZ MH)-!F=?&G4P>\>,/)0V9_^?BHO\+IM'
MOA]PQ'P@$Z4/I 5- (V9 ").PBB /I34ND/6,\>Q(?K\X+!J'^DS2*/5\1"Z
M9NC  V@WFR8^?+9RR/W0N>W!^ /G6LR?<]C<3JKWH+ECJ$/?._\AB[>)J>"\
MM.GEUL<?T6>OTN7]=Z/L?WMJYW9EZ];/;42:KJ';E4"CH]LY8&2A^)PO2[;X
M3WI3=13C6$90QC'P?2Q!R+$^%>.Q DJBB$K&"$7*J58TICGV<K$2ZVFU3DW;
M3F<'%@UGOR:N&[96N9>.3B?&5X]FV)]30#I3ZZTAW:-=\3^3F5Y'%A\R(>__
M+1_FB:!"\8B!! ;F:RTB!1A6!& "E> XB@-H?<E"YPQ'"OU:I5?)]+3.H;0_
M-](6]!'V3,.XO3,.</=D/X+KYQ$G1KHGH3;-?0/=OX[BW3V_TN^?K+I_!,8,
M(1@"%5"J.0X0H*SZ%?E*8840BX9^)45]@F/#>*/1VX@<V$+M-'$WPV.M.3#"
M UUQ^G**KM1'?4%%(^#D7U+1E4[7%U5TCNN#M^[XN7YT^F+S3+KZQOS3%_\'
M4$L#!!0    ( +""8544G8*<W 8  .TR   5    87%S="TR,#(R,3$P,5]P
M<F4N>&ULU9M9<]PV$L??]2DFD]>%!B . BI+*:UBIU2KQ"I;*:?RPL+1&+',
M(162NK[]-CF28QW.<D56B7Z9@P31C7__!F@T.6]^NMD4BRNHF[PJ]Y=LERX7
M4/HJY.5Z?_G[V3NBES\=[.R\^8&0/_[]X63Q<^4O-U"VBZ,:; MA<9VWYXM/
M 9K/BUA7F\6GJOZ<7UE"#OJ+CJJ+VSI?G[>+A";)X[/UGC91*JX],0D+1"02
M/Z6&$F"!2F]]D#3YUWK/4.%#XC6AW'3-J"&::DD$%Q&HTMR;I.^TR,O/>]V+
MLPTL<'!ETW_=7YZW[<7>:G5]?;U[X^IBMZK7JX12OKIOO;QK?O.D_37O6S-C
MS*H_^Z5IDS_7$+MEJS]^/?GHSV%C25XVK2U]9Z#)]YK^X$GE;=MK_C_]6GRS
M1?>-W#<CW2'"$L+9[DT3E@<[B\56CKHJX /$1??^^X?C+R;M7Y?0M/D5[/IJ
ML^K.KHXJ9 '][*]K;R]@?]GDFXL"[H^=UQ#WE_:OIB5=0!FCO;4?MQ>N_C9Z
M44.#G/2#/,$#=]=W5OY/!^"FA3+ =D3WW1>5?]"HZ/2LOEQ96 =%?S0+D&=]
MKX>N:6OKVXSZ1"H6*6$^($RI"\3P((ERRG&$#-(T/!QOYV^##O?R-^!WU]75
M"CO&,"2L^]")L17BB;FM*"_S^_[7=H9M,^ZY\RYRHBQ%\JVDQ#J3$AQ,2L$Z
M(;0?Y?;7UAYZ_74P#VN_J.H -4X7]^9L[1\$]BFJ=RU6%[;&CH@_SXLO&G?S
MQA2Q:JL)E-N&!=U=+G#4$>H:PLDV*M\<7#^R%B=1Z%M.$?%3J/,JO"W#SSC+
M9L!!&JLY 0>*" \"!Z!0%,42ZT*408A)0O_ [" &DODS\'(M7QF&MV6;M[<?
M8)UW2I3M;W8#F4X#\NQ3XE$.7 HA=C #4<"L4*F&Q,$H%IZS.@@%/E\41BLY
M"Q*.,3.K+ZJZ%_XCZ@]'U679UK='58",T02S)4B),)A%">4%T1Q58DY:QR$
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MPWNG"3PZ<;WY:R,.C*N%^Y'[WWUC#;KG1JO9@7MWAM(1&+8#(O4U$4:Z'/P
M%I3/7;\W7/\O;J.,-LY"O@#A*G]4EBHT"6PE@1M[QIW$ QJX\IU&,&E\G+&(
M&VWC["KXV'YMS#F/$>7W;CPS?GIW80 R4GQ-@A#^GX3PU7_R]U_CY]GP\S/W
M@>?B'0U RAC?MGL&O-K#.^'ZAL\9B'P>S@T_\!N.ZR5TBR>)CTL9\2P,DNG,
MF ,/=A=PYV+4>AE=J:@TEC1O+8.X"]\/$M^&MT0Q(G#JVH;#;3="U"&C^[*
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MEWH? 08#!)*R4-\-P3 /$&Q-@+HC4UD>!4+J*J*\(&#!:.ZPI2!,9,CY%8!
MONTTL_Q;PJ([*8K_5*9*[&W:HBD@)%^>=[S#TNBKQFBTV(5P?CI! C!L.*"5
MQ488+('F$3X!)@##K6>>4+]S&]G^\F,PWG9T">:EMV)'E,G! %0$F8PJ!.?Y
M#4T'B725# ?H^O772V1$43*.7)"%(:F<%U&$93^!\0O8#I@!JA+LI :HOI=J
M'Z79D8<!L+?<EG!'(6 D><>=4"YC[%( )'7:93H=I<HI%!LW2UC@;Z8R#<YL
M9)I_L_EK2GH0N4BI?>?\E?BVT 3S["_E;RR* EN\F,#R*P>-_0L>I#4\_QD8
M$4L NTO?@2O""X860^89WP=% PO>2_:5<98RYQ1Z:Y@0'#I_C5'ACM+(S=8?
M%A&N3&$RJR1C@XN'N5OWH,*E@$/CEO+^8F# '-B=R,#"D(8PJ!1D$=KIRW-^
M'$J_?W1S@@&N<QED*J-F2S$5X.1[G'N%JZ>,Q?BVGRV]SEPR\\/%PYYU6J\-
MARU5R#!=]1_2X;20SD6PWER;R_R4X)[<:9E'/6\=&A\9>@R(B=VB\QCM,IF
M9YQ]O/WMM3I>YEA?R)\($X]D GGI;RC.!^*O:5C][[[I#LY[?<OL#3I"E*HS
MC9<%,I#+DRA!:L@VS*5[5SV9R@)\_L$CPK[E*UUG^^K(GE-^E$8M,0=.,7P3
M+%R%ZUW)NH#@3!30WM(UU$5'R9#S\9'P5,FXJV;U8U16!!:PQ6"5IZ+J)(I1
MUI0\XB(ZLE:+R)HB =-8Y'3*^YEKSPJ4Z&[4&C,&NUU_!%I+F2I^4:#I8CHH
MW*-MQ/TX05,.WBHM'K7^L]T<RS1=X]M!3B@H>62S:%94?7]A;F0'*\J0\3,
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M$6J;T^HCK*WB)9I9%=Z/9R%(RT.0;W[#B^V$NE/XXMTBAS9"-29-H13]4CP
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MH_.:>Q!N9,L,I+%BEI! J<A D0<_0^(1/6U$+-^7RC)28^)&,Z4P8 M6,(@
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MW>&<+QC;;I.CX_<_KFYNK_]]9=S^<O7IXN/5'[?7ES>F<?WALKF5(*JR^<O
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M:MQ"J%NB'X5N\/32V.D=IK^3QLYNW4(ZNK5@E='3+R%,GQ$]IQ!W3=-SPWP
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MLM-U:9G=KKXN^KKHZ[)3D&]@]H=UG+VLKXN^+@>X+AUSU!W6];H<]73:-^/
M6<(?LWCN_?#_ 5!+ 0(4 Q0    ( +""856ZT@WW?!0  !61   1
M      "  0    !A<7-T+3(P,C(Q,3 Q+FAT;5!+ 0(4 Q0    ( +""854-
M SHJ: (  &4'   1              "  :L4  !A<7-T+3(P,C(Q,3 Q+GAS
M9%!+ 0(4 Q0    ( +""8542-04(I0H  /]@   5              "  4(7
M  !A<7-T+3(P,C(Q,3 Q7VQA8BYX;6Q02P$"% ,4    " "P@F%5%)V"G-P&
M  #M,@  %0              @ $:(@  87%S="TR,#(R,3$P,5]P<F4N>&UL
M4$L! A0#%     @ L()A50D'4/2]/@  D$(# !8              ( !*2D
M &%Q<W0M<3-X,C R,GAE>#DY,2YH=&U02P4&      4 !0!( 0  &F@

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
